首页> 外文OA文献 >Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

【2h】

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

机译：在随机研究中更新了整体存活，将Dacomitinib与Gefitinib作为先进的非小细胞肺癌和EGFR活化突变患者的一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tony S. Mok; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Alka Chawla; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Kay Noonan; Yiyun Tang; Malaika Pastel; Keith D. Wilner; Yi-Long Wu;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations [J] . Mok Tony S., Cheng Ying, Zhou Xiangdong, Journal of Clinical Oncology . 2018,第22期

机译：随机研究中整体存活的改善，使Dacomitinib与吉替尼在高级非小细胞肺癌和激活突变患者中将Daccitinib进行比较
2. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial [J] . Wu Yi-Long, Cheng Ying, Zhou Xiangdong, The lancet oncology . 2017,第11期

机译：Dacomitinib与Gefitinib为EGFR-突变阳性非小细胞肺癌（Archer 1050）的患者的一线治疗：随机，开放标签，第3阶段试验
3. Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase Ilb trial LUX-Lung 7 [J] . OByrne K. J., Park K., Tan E., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Suppla1期

机译：阿法替尼vs吉非替尼作为一线治疗患有激活性EGFR突变的晚期非小细胞肺癌（NSCLC）患者：全球，随机，开放标签，IIb期lb-lung试验的结果LUX-Lung 7
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Cost-effectiveness and safety of the molecular targeted drugs afatinib gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer [O] . M. Kimura, F. Yasue, E. Usami, -1

机译：分子靶向药物afatinibgefitinib和erlotinib作为晚期EGFR突变阳性非小细胞肺癌患者的一线治疗的成本效益和安全性
7. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer [O] . H. Yoshioka, M. Shimokawa, T. Seto, 2019

机译：WJTOG3405的最终总体生存结果，将GEFITINIB与CISPLATIN与Docetaxel作为阶段IIIB / IV或术后复发性EGFR突变阳性阳性非小细胞肺癌的一线治疗的随机期III试验

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

著录项

引文网络

相似文献

相关主题

期刊订阅